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These are exciting times in cancer research; significant ad-
vances in cancer biology are now being effectively trans-
lated into the clinic and technological advances such as
gene expression profiling are allowing the characterisa-
tion of cancerous lesions at the molecular level and the
identification of markers of prognostic value. In this con-
text, I am proud to introduce Molecular Cancer  [http://
www.molecular-cancer.com], a new forum for cutting-
edge findings in cancer research.
This open access, online journal is interested in a wide
range of manuscripts presenting original research and
commentary. For original research, the common thread is
that the work should reveal novel concepts of broad im-
portance to the scientific community. Molecular Cancer
publishes Reviews, Original research, Case reports, Short
communications and Hypotheses.
Reviews are invited and should be of public interest. The
common thread of Original research and Case reports is
that they reveal novel concepts of wide importance and
interest to the scientific community, with conclusions that
deliver a substantial advance in understanding of an im-
portant problem. Short communications are preliminary
results of exceptional interest that are particularly topical
and relevant, and for which fast publication is essential.
Hypotheses are ideas or critics of ideas with discussion
that will deliver a substantial advance in the understand-
ing of an important problem.
I obtained my Ph.D. from the University of Rostock, Ger-
many, for my work on mechanotransduction [1]. From
my collaborations with scientists at biotech companies
and with clinicians, I came to recognise the need for a dy-
namic forum that fosters the exchange of ideas across the
entire cancer community. We now have an opportunity to
make Molecular Cancer just such a journal, and this is an
exciting challenge. Assisting me in this new venture are
Guido M. Sclabas, as Deputy Editor, and R. Scott Heller as
Associate Editor. Guido has a background in surgical on-
cology and growth factor signalling. Scott's research focus-
es on Wnt signalling and pancreas development.
For Molecular Cancer to become an exciting forum for can-
cer research, we need you to contribute your most innova-
tive and significant work in the cancer field. In exchange,
Molecular Cancer will strive to provide a fast, fair, and con-
structive review process; the highest quality production
values; and a dedicated team of professional scientific ed-
itors, who are willing to discuss your research, respond to
your presubmission inquiries, and ensure that all manu-
scripts are reviewed on the basis of scientific merit and
held to the highest standards of excellence and editorial
consistency.
I would like to take this opportunity to acknowledge our
Editorial Board  [http://www.molecular-cancer.com/ed-
board/] for their commitment to the journal and to ex-
press my most sincere gratitude to the entire staff of
BioMed Central  [http://www.biomedcentral.com/] for
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nal.
I invite you to work together with us to develop this new
forum for cancer research, and I look forward to meeting
you at conferences throughout the year.
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